Top PDF (2R,3S,4R) 1,2,4,5 Tetra­acet­oxy 3 meth­oxy­pentyl acetate

Methyl (E,E) {2 [({[1,3 di­methyl 5 (2 fluoro­phen­­oxy) 1H pyrazol 4 ylmethyl­ene]amino}­­oxy)meth­yl]phen­yl} 2 (meth­oxy­imino)acetate

Methyl (E,E) {2 [({[1,3 di­methyl 5 (2 fluoro­phen­­oxy) 1H pyrazol 4 ylmethyl­ene]amino}­­oxy)meth­yl]phen­yl} 2 (meth­oxy­imino)acetate

The molecule of (I) displays a U-shaped conformation (Fig. 1), the dihedral angles formed by the benzene rings C1– C6 and C14–C19 with the central N1/N2/C7/C8/C9/C12/N3/ O2/C13 unit being 80.88 (7) and 87.91 (8) , respectively. As observed in 4-cinnamoyl-1,3-dimethylpyrazol-5-one (Guard & Steel, 1994) and 4-(5-hydroxy-1,3-dimethyl-4-pyrazolyl- methylene)-1,3-dimethyl-2-pyrazolin-5-one (Dru¨ck & Littke, 1980), the N1—C7 single bond is significantly shorter than the N1—N2 single bond (Table 1). The torsion angles C22—C20— N4—O3 and C8—C12—N3—O2 are 177.8 (6) and 179.0 (2) ,
Show more

10 Read more

Synthesis and Antioxidant Ability of Some 4-(((4-(5-(Aryl)-1,3,4-Oxadiazol-2-Yl)Benzyl)Oxy)Methyl)-2,6-Dimethoxyphenol

Synthesis and Antioxidant Ability of Some 4-(((4-(5-(Aryl)-1,3,4-Oxadiazol-2-Yl)Benzyl)Oxy)Methyl)-2,6-Dimethoxyphenol

for the aryl group of 5-aryl-1,3,4-oxadiazole besides their substituted group. For example, the methyl group of compound 6a appeared as signal peak at 2.32 ppm with integration of three protons also the ethoxy group of compound 6c exhibited as two signal the first one appeared as triplet peak at 1.45 with coupling constant(J) equal 7.42 Hz and the second one appeared as quartet peak at 4.14 with J= 7.8 Hz. The 13C NMR spectra of these compounds exhibited disappearing the carbonyl group of the starting material as well new two interesting peaks at 162.43-164.68 ppm and 164.77-165.88 ppm indicated the two carbons, C 11 and C 12 of C=N in oxadiazole ring. All expected carbons were appeared at their expected area. The EIMS spectra exhibited the molecular ion M •+ for all newly synthesized
Show more

9 Read more

3 {2 [(3 {(E) 2 [4 (Di­methyl­amino)­phen­yl]ethen­yl}quinoxalin 2 yl)­­oxy]eth­yl} 1,3 oxazolidin 2 one monohydrate

3 {2 [(3 {(E) 2 [4 (Di­methyl­amino)­phen­yl]ethen­yl}quinoxalin 2 yl)­­oxy]eth­yl} 1,3 oxazolidin 2 one monohydrate

2-Chloro-3-(4-dimethylaminostyryl)quinoxaline is a reactant for the synthesis of quinoxaline derivatives that possess anti-cancer properties (Noolvi et al., 2011); the chloro substitutent is exchanged for other organic radicals. We have used the 3-(4-dimethylaminostyryl)quinoxaline as reactant to furnish the title derivative (Scheme I). The quinoxaline fused- ring and the phenylene ring are nearly co-planar (dihedral angle 2.52 (2)°) (Fig. 1). The water molecule is hydrogen bond donor to an N atom of the fused-ring as well as an O atom of the oxazolinone unit, the two hydrogen bonds generating a linear chain running along the c-axis of the monoclinic unit cell (Table 1).
Show more

8 Read more

(1S,2S) 1 {2 [(4 Meth­oxy­benzyl)­­oxy]­ethyl} 2 methyl 3 butenyl (1S,4R) 4,7,7 tri­methyl 3 oxo 2 oxabi­cyclo­[2 2 1]­heptane 1 carboxyl­ate

(1S,2S) 1 {2 [(4 Meth­oxy­benzyl)­­oxy]­ethyl} 2 methyl 3 butenyl (1S,4R) 4,7,7 tri­methyl 3 oxo 2 oxabi­cyclo­[2 2 1]­heptane 1 carboxyl­ate

To a solution of 1-[(4-methoxybenzyl)oxy]-4-methylhex-5-en-3-ol (0.91 mmol), (1), in dry dichloromethane (1 ml) was added triethyl- amine (1.27 mmol) and 4-dimethylaminopyridine (0.091 mmol), followed by (1S)-(ÿ)-camphanic chloride (1.36 mmol). After 2 h the solution was diluted with CH 2 Cl 2 (5 ml) and 1 N HCl was added

8 Read more

The crystal structures of two new coumarin derivatives: 2 (4 {2 [(2 oxo 2H chromen 4 yl)­­oxy]acet­yl}piperazin 1 yl)acetamide and N (2,4 di­meth­­oxy­benz­yl) 2 [(2 oxo 2H chromen 4 yl)­­oxy]acetamide

The crystal structures of two new coumarin derivatives: 2 (4 {2 [(2 oxo 2H chromen 4 yl)­­oxy]acet­yl}piperazin 1 yl)acetamide and N (2,4 di­meth­­oxy­benz­yl) 2 [(2 oxo 2H chromen 4 yl)­­oxy]acetamide

Coumarin and its derivatives represent one of the most active classes of compounds possessing a wide spectrum of biological activity. The synthesis, and pharmacological and other prop- erties of coumarin derivatives have been studied and reviewed (Kumar et al., 2015; Kubrak et al., 2017; Srikrishna et al., 2018; Venugopala et al., 2013). Many of these compounds have proven to be active as antibacterial, antifungal, anti-inflam- matory, anticoagulant, anti-HIV and antitumor agents. One of the title compounds, 2-(4-{2-[(2-oxo-2H-chromen-4-yl)oxy]- acetyl}piperazin-1-yl)acetamide (I), has been shown to exhibit antimicrobial as well as antioxidant activity (Govindhan, Subramanian, Chennakesava Rao et al., 2015; Govindhan, Subramanian, Sridharan et al., 2015). In view of the impor- tance of their natural occurrence, biological activities, phar- macological and medicinal activities, and utility as synthetic intermediates, we have synthesized the title 2-[(2-oxo-2H-
Show more

17 Read more

Synthesis of aryl {4 [({5 [3 (methylsulfonyl)phenyl]pyrazin 2 yl} oxy)methyl]piperidin 1 yl}methanones

Synthesis of aryl {4 [({5 [3 (methylsulfonyl)phenyl]pyrazin 2 yl} oxy)methyl]piperidin 1 yl}methanones

A mixture of HCl in dioxane (10 mL) and tert-butyl 4-((5-(3-(methylsulfonyl) phenyl) pyrazine-2-yloxy) methyl) piperidine-1-carboxylate was stirred at room temperature for overnight (monitored by TLC), and the solvent was removed in vacuo. Water and ethyl acetate was added to the above crude product and stirred well. The organic layer was separated and the major impurities were removed in the organic layer. The aqueous layer was basified using sodium hydroxide solution and the product was extracted with DCM (100 mL × 3). The combined organic layers were washed with water followed by brine solution and dried over anhydrous Na 2 SO 4 . The solvent was evaporated
Show more

11 Read more

Crystal structure of hexa­prop 2 en 1 yl 4,4′,4′′,4′′′,4′′′′,4′′′′′ [1,3,5,2λ5,4λ5,6λ5 tri­aza­triphosphinine 2,2,4,4,6,6 hexa­yl­hexa­kis­(­­oxy)]hexa­benzoate

Crystal structure of hexa­prop 2 en 1 yl 4,4′,4′′,4′′′,4′′′′,4′′′′′ [1,3,5,2λ5,4λ5,6λ5 tri­aza­triphosphinine 2,2,4,4,6,6 hexa­yl­hexa­kis­(­­oxy)]hexa­benzoate

A mixture of hexachlorocyclotriphosphazene (1.04 g, 3 mmol), allyl 4-hydroxybenzoate (3.75 g, 21 mmol), and activated potassium carbonate (3.5 g, 253 mmol) in tetrahydrofuran (50 ml) was stirred at 66 °C for 45 h under nitrogen. The resulting suspension mixture was filtered and the filtrate was concentrated, leading to the formation of a faint yellow viscous liquid. It was dissolve in 20 ml ethyl acetate, and the solution was added dropwise to methanol. Colourless needle crystals suitable for X-ray diffraction analysis were obtained by slow evaporation of the solvent after about 2 days. S3. Refinement
Show more

16 Read more

Synthesis and in vitro antitumor activity of (1E,4E)-1-aryl-5-(2-((quinazolin-4-yl)oxy)phenyl)-1,4-pentadien-3-one derivatives

Synthesis and in vitro antitumor activity of (1E,4E)-1-aryl-5-(2-((quinazolin-4-yl)oxy)phenyl)-1,4-pentadien-3-one derivatives

Results: A series of (1E,4E)-1-aryl-5-(2-((quinazolin-4-yl)oxy)phenyl)-1,4-pentadien-3-one derivatives (curcumin analogs) were synthesized and characterized by IR, NMR, and elemental analysis techniques. All of the prepared compounds were screened for antitumor activities against MGC-803, PC3, and Bcap-37 cancer cell lines. A significant inhibition for cancer cells were observed with compound 5f and also less toxic on NIH3T3 normal cells. The mecha- nism of cell death induced by compound 5f was further investigated by acridine orange/ethidium bromide staining, Hoechst 33,258 staining, TUNEL assay, and flow cytometry cytometry, which revealed that the compound can induce cell apoptosis in MGC-803 cells.
Show more

10 Read more

Crystal structure of 2 {[(naphthalen 1 yl)­oxy]meth­yl} 5 (2,4,5 tri­fluoro­phen­yl) 1,3,4 oxa­diazole

Crystal structure of 2 {[(naphthalen 1 yl)­oxy]meth­yl} 5 (2,4,5 tri­fluoro­phen­yl) 1,3,4 oxa­diazole

Iodobenzene diacetate (2.0 mol eq) was added to a solution of naphthalen-1-yloxy-acetic acid (2, 4, 5-trifluoro-benzyl- idene)-hydrazide (1.0 mole eq) in dioxane (10mL) at 25-30 ° C and stirred at the same temperature for 15-30 minutes. Completion of the reaction was confirmed by TLC (mobile phase ethyl acetate/hexane, 3:7). The dioxane was distilled off under vacuum. The resulting residue was dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution, followed by water and brine solution. The separated organic layer was dried over anhydrous sodium sulfate and distilled under vacuum. The crude product was purified by column chromatography over silica gel (60-120 mesh) using hexane and ethyl acetate (9:1) as eluent to afford the pure product of as an off-white solid. After purification the compound was crystallized from methanol by the slow evaporation method.
Show more

9 Read more

Drug-likeness and antimicrobial activity of 5-(4-bromophenyl)-3-{3-methyl-4- [(4-substitutedbenzyl)oxy]phenyl}-4,5-dihydro-1,2-oxazole

Drug-likeness and antimicrobial activity of 5-(4-bromophenyl)-3-{3-methyl-4- [(4-substitutedbenzyl)oxy]phenyl}-4,5-dihydro-1,2-oxazole

Drug-likeness is equilibrium amongst the molecular properties of a compound which directly affects pharmacodynamics and pharmacokinetics of a drug in human body [16]. A variety of pharmacophoric features including hydrophobicity, molecular dimension, and flexibility control the activities of molecules in a living system. During the last few years there are numerous models being proposed to relate structure-bioavailability relationship [17-19]. Possibly the best known of these studies is the ‘rule-of-five’ given by Lipinski [14]. Depending on these four molecular descriptors, the approach generates a vigilant about apparent absorption trouble if at least two of the following conditions are fulfilled: (1) calculated log P >5 (2) molecular weight >500; (3) total number of hydrogen- bond acceptors >10; (4) total number of hydrogen-bond donors >5. Absorption, polar surface area, and ‘‘rule of five” properties
Show more

7 Read more

4 (4 Fluoro­phen­yl) 2 methyl 3 (1 oxy 4 pyridyl)isoxazol 5(2H) one

4 (4 Fluoro­phen­yl) 2 methyl 3 (1 oxy 4 pyridyl)isoxazol 5(2H) one

For the synthesis of 2-(4-fluorophenyl)-3-oxo-3-pyridin-4-yl-N-oxide-propionic acid ethyl ester (see Fig. 3), to a suspension of 10 g (72 mmol) of isonicotinic acid N-oxide in 15 ml of DMF, 19.7 g (121 mmol) of CDI were added. The reaction mixture was stirred at 298 K for 1 h. The limpid solution was then cooled at 273 K and 13.3 g (72 mmol) of (4- fluorophenyl)acetic acid ethyl ester and 4.1 g (168 mmol) of NaH were added. The reaction mixture was stirred at 273 K for 15 min, then the temperature was raised to 298 K and kept under vigorous stirring for 4 h. The reaction mixture was then poured into water/ice, the pH adjusted to 6, and the solution extracted with ethyl acetate. The combined organic layers were then collected, dried over Na 2 SO 4 and concentrated under vacuum, affording an oil that was chromatographed
Show more

9 Read more

N [2 ({[1 (4 Chloro­phen­yl) 1H pyrazol 3 yl]­­oxy}meth­yl)phen­yl] N meth­­oxy­hydrazinecarboxamide

N [2 ({[1 (4 Chloro­phen­yl) 1H pyrazol 3 yl]­­oxy}meth­yl)phen­yl] N meth­­oxy­hydrazinecarboxamide

In the title compound all bond lengths and angles are normal and correspond to those observed in the related structure (Attia et al., 2012). The hydrazinecarboxamide moiety (N2,N5,N6/O1/C1) is nearly planar with a maximum deviation of 0.074 (2) Å at atom N6, and is inclined at an angle of 57.43 (7)° with the benzene ring (C7–C12). The dihedral angle between the benzene rings is 34.07 (6)°. Chlorophenyl group makes a dihedral angle of 19.71 (7)° with the pyrazole ring. In the crystal, N6—H61···O1 hydrogen bonds link pairs of molecules to form inversion dimers and dimers are connected via N6—H62···N15 and N5—H51···N6 hydrogen bonds to form chains along the a axis of the unit cell (Table 1, Fig. 2).
Show more

9 Read more

Methyl ({[(4E) 1,3 di­methyl 2,6 di­phenyl­piperidin 4 yl­­idene]amino}­­oxy)acetate

Methyl ({[(4E) 1,3 di­methyl 2,6 di­phenyl­piperidin 4 yl­­idene]amino}­­oxy)acetate

C3 0.0623 (16) 0.081 (2) 0.0624 (17) 0.0243 (14) 0.0081 (14) 0.0244 (14) C4 0.0731 (17) 0.0438 (14) 0.090 (2) 0.0148 (13) 0.0279 (15) 0.0214 (14) C5 0.0514 (13) 0.0458 (13) 0.0627 (15) 0.0006 (11) 0.0123 (12) −0.0008 (11) C6 0.0406 (11) 0.0401 (12) 0.0344 (11) 0.0043 (9) 0.0078 (9) 0.0030 (9) C7 0.0425 (12) 0.0414 (11) 0.0346 (11) 0.0001 (9) 0.0043 (9) −0.0041 (9) C8 0.0427 (12) 0.0629 (14) 0.0328 (11) 0.0124 (10) 0.0071 (10) 0.0051 (10) C9 0.0405 (11) 0.0458 (12) 0.0315 (11) 0.0015 (9) 0.0091 (9) 0.0032 (9) C10 0.0438 (11) 0.0429 (12) 0.0342 (11) 0.0044 (9) 0.0065 (9) −0.0005 (9) C11 0.0350 (10) 0.0447 (11) 0.0365 (11) −0.0002 (9) 0.0028 (9) −0.0046 (9) C12 0.0478 (13) 0.0468 (12) 0.0349 (11) 0.0055 (10) 0.0130 (10) 0.0030 (9) C13 0.0483 (14) 0.0612 (15) 0.0672 (16) 0.0038 (11) 0.0174 (12) 0.0001 (12) C14 0.0597 (16) 0.0826 (19) 0.088 (2) 0.0216 (14) 0.0294 (15) 0.0069 (16) C15 0.099 (2) 0.079 (2) 0.0726 (19) 0.0311 (17) 0.0398 (17) −0.0027 (16) C16 0.101 (2) 0.0803 (19) 0.0580 (16) 0.0145 (16) 0.0181 (16) −0.0243 (14) C17 0.0589 (14) 0.0685 (16) 0.0455 (13) 0.0077 (12) 0.0061 (12) −0.0092 (12) C18 0.0643 (15) 0.0670 (16) 0.0537 (14) 0.0106 (12) 0.0265 (12) 0.0184 (12) C19 0.0609 (14) 0.0614 (15) 0.0524 (14) 0.0172 (12) 0.0105 (12) 0.0028 (11) C20 0.0788 (16) 0.0557 (14) 0.0283 (11) 0.0030 (12) 0.0058 (11) −0.0052 (10) C21 0.0581 (13) 0.0516 (14) 0.0383 (12) 0.0028 (12) 0.0107 (11) −0.0102 (10) C22 0.105 (2) 0.0694 (17) 0.0589 (16) 0.0111 (15) 0.0129 (15) 0.0156 (13)
Show more

9 Read more

Methyl 2 {[2 (4,4,5,5 tetra­methyl 1,3 dioxyl 4,5 di­hydro­imidazol 2 yl)phen­yl]­­oxy}acetate

Methyl 2 {[2 (4,4,5,5 tetra­methyl 1,3 dioxyl 4,5 di­hydro­imidazol 2 yl)phen­yl]­­oxy}acetate

Data collection: APEX2 (Bruker, 2007); cell refinement: SAINT (Bruker, 2007); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 1997); software used to prepare material for publication: SHELXTL (Sheldrick, 2008) and PLATON (Spek, 2009).

8 Read more

1 [3 (Morpholin 4 yl)prop­yl] 3 [(naph­tha­len 2 yl)­oxy] 4 (3 nitro­phen­yl)azeti­din 2 one

1 [3 (Morpholin 4 yl)prop­yl] 3 [(naph­tha­len 2 yl)­oxy] 4 (3 nitro­phen­yl)azeti­din 2 one

one) ring is nearly planar [maximum deviation = 0.011 (3) A ˚ ]. The mean plane formed by the four C atoms of the morpholine ring, which adopts a chair conformation, the benzene ring and the naphthalene ring system form dihedral angles of 72.85 (17), 87.46 (15) and 65.96 (11) , respectively,

11 Read more

Crystal structure of 2 (4 fluoro 3 methyl­phen­yl) 5 {[(naphthalen 1 yl)­­oxy]meth­yl} 1,3,4 oxa­diazole

Crystal structure of 2 (4 fluoro 3 methyl­phen­yl) 5 {[(naphthalen 1 yl)­­oxy]meth­yl} 1,3,4 oxa­diazole

Data collection: APEX2 (Bruker, 2008); cell refinement: SAINT (Bruker, 2008); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012); software used to prepare material for publication: SHELXL97 and PLATON (Spek, 2009).

9 Read more

DESIGN, SYNTHESIS AND STRUCTURAL ELUCIDATION OF ARYLOXYAMINOACETYLENIC DERIVATIVES AS ANTIDEPRESSANT ACTIVITY

DESIGN, SYNTHESIS AND STRUCTURAL ELUCIDATION OF ARYLOXYAMINOACETYLENIC DERIVATIVES AS ANTIDEPRESSANT ACTIVITY

7-methoxy-2-naphtol, propargyl bromide, cyclic amine, 1-methylpiperazine 99%, 2- methylpiperidine 98%, Cis-2,6-Dimethylpiperidine 98%, hexamethyleneimine (Azepane) 99%, pyrrolidine 99%, piperidine 99% (Sigma Aldrich, USA), potassium carbonate anhydrous (Gainland Chemical Company, UK), potassium hydroxide (Lonover, UK), para formaldehyde polymer (BDH chemicals Ltd Poole, England), potassium bromide (Scharlau, Spain), cuprous chloride LRG (East Anglia Chemicals, Hadleighlpswich), acetonitrile 99.7% (PanReAcQuimca SA, EU), 1,4-dioxane (FULL Time, China ), chloroform (TEDIA, USA), dimethyl sulfoxide (DMSO) (BBC Chemicals for lab, EU).
Show more

10 Read more

5,10,15,20 Tetra­kis­­[(4 ethyl­carbonyl)­­oxy]­phenyl­porphyrin† †

5,10,15,20 Tetra­kis­­[(4 ethyl­carbonyl)­­oxy]­phenyl­porphyrin† †

The structure of the porphyrin core is very similar to other free base porphyrins (Silvers & Tulinsky, 1967, Chen & Tulinsky, 1972, Codding & Tulinsky, 1972, Little & Ibers, 1975). The chemically equivalent bonds around the 24 atom core have similar bond lengths. The 24 atom core is planar with an r.m.s. deviation from the the plane of 0.021 (3) Å, and the two independent pyrrole ring planes are tilted slightly at an angle of 2.1 (3)°. The imino H atoms are displaced on opposite sides with respect to the porphyrin macrocycle. The distance between the two imino H atoms is 2.33 (4) Å, which is slightly shorter than those values found in porphine (2.41 Å), and comparable with those in TPP (2.36 Å) and octaethylporphyrin (OEP) [2.36 (4) Å] (Codding & Tulinsky, 1972, Silvers & Tulinsky, 1967, Lauher & Ibers, 1973). The imino H atoms form bifurcated intramolecular hydrogen bonds with the adjacent unprotonted N atoms (Table 2). Owing to the steric effect of the bulky phenyl group, the four planes of the phenyl groups are almost perpendicular to the porphyrin macrocycle. Therefore, the angles between the planes of the first pyrrole ring containing N1 and its
Show more

13 Read more

Crystal structure of 4 [(3 methyl­but 3 eno­yl)­­oxy]phenyl 4 n hexyl­oxybenzoate

Crystal structure of 4 [(3 methyl­but 3 eno­yl)­­oxy]phenyl 4 n hexyl­oxybenzoate

In the crystal, only C9—H9 O1 contacts between trans- lationally (along the a axis) related molecules may be considered to be weak hydrogen bonds (Table 1, Fig. 4). The H9 O1 distances are equal to 2.47 A ˚ , which corresponds to common values. The H9 atom is rather acidic to participate in a weak hydrogen bond since it is situated at the ortho position to the accepting ester group. A detailed analysis of the crystal

10 Read more

3 {2 [(3 Phenyl­quinoxalin 2 yl)­­oxy]ethyl} 1,3 oxazolidin 2 one

3 {2 [(3 Phenyl­quinoxalin 2 yl)­­oxy]ethyl} 1,3 oxazolidin 2 one

3-Phenyl-quinoxalin-2-one (1.25 mmol, 0.28 g), di(chloroethyl)amine hydrochloride (2.66 mmol, 0.50 g), potassium carbonate (4.00 mmol, 0.52 g) and tetra- n -butylammonium bromide (0.01 mmol, 0.003 g) were heated in DMF (40 ml); the progress of the reaction was monitored by thin layer chromatography. On completion, the solvent was removed under reduced pressure and the residue was chromatographed on silica column ( n -hexane/ethyl acetate:4/6). Recrystallization was effected by using the sample solvent system.

10 Read more

Show all 10000 documents...